Tags

Type your tag names separated by a space and hit enter

Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis.
Bone Marrow Transplant. 1994 Mar; 13(3):247-52.BM

Abstract

Ninety-one patients with de novo acute myeloid leukemia (AML) in first complete remission (CR) undergoing an HLA-identical sibling BMT and with a minimum follow-up of 12 months were analyzed for disease-related and transplant-related variables predicting survival and relapse. The overall actuarial 5 year survival is 53% and the relapse rate 29%, with a medium follow-up for surviving patients of 1552 days (range 365-4094 days). In univariate analysis the following variables were found to be associated with an increased risk of failure: high-dose cyclosporin (CsA), M4-M6 FAB subtype and a long interval (> or = 180 days) between diagnosis and BMT. Other disease-related variables at presentation were not significant, including WBC count > 50 x 10(9)/l, marrow blasts < 70%, time to enter remission > 40 days and > 2 courses to enter remission. Survival was 58% vs 43% for M1-M3 vs M4-M6 FAB subtypes (p = 0.03) and 71% vs 42% for low-dose vs high-dose CsA (p = 0.01). A multivariate analysis was then run separately on survival, relapse and transplant related mortality (TRM). Survival was negatively influenced by M4-M6 FAB subtypes (p = 0.009), high-dose CsA (p = 0.03) and a long interval between diagnosis and BMT (p = 0.04). Leukemia relapse was higher in patients receiving high-dose CsA (p = 0.003) and in females (p = 0.04). Transplant-related mortality was higher in FAB M4-M6 patients (p = 0.01) and patients grafted late after diagnosis (p = 0.03).(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Divisione Ematologia 2, Ospedale San Martino, Genova, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8199567

Citation

Fagioli, F, et al. "Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia in First Complete Remission: the Effect of FAB Classification and GVHD Prophylaxis." Bone Marrow Transplantation, vol. 13, no. 3, 1994, pp. 247-52.
Fagioli F, Bacigalupo A, Frassoni F, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis. Bone Marrow Transplant. 1994;13(3):247-52.
Fagioli, F., Bacigalupo, A., Frassoni, F., Van Lint, M. T., Occhini, D., Gualandi, F., Lamparelli, T., Clavio, M., Vitale, V., & Sogno, G. (1994). Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis. Bone Marrow Transplantation, 13(3), 247-52.
Fagioli F, et al. Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia in First Complete Remission: the Effect of FAB Classification and GVHD Prophylaxis. Bone Marrow Transplant. 1994;13(3):247-52. PubMed PMID: 8199567.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis. A1 - Fagioli,F, AU - Bacigalupo,A, AU - Frassoni,F, AU - Van Lint,M T, AU - Occhini,D, AU - Gualandi,F, AU - Lamparelli,T, AU - Clavio,M, AU - Vitale,V, AU - Sogno,G, PY - 1994/3/1/pubmed PY - 1994/3/1/medline PY - 1994/3/1/entrez SP - 247 EP - 52 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 13 IS - 3 N2 - Ninety-one patients with de novo acute myeloid leukemia (AML) in first complete remission (CR) undergoing an HLA-identical sibling BMT and with a minimum follow-up of 12 months were analyzed for disease-related and transplant-related variables predicting survival and relapse. The overall actuarial 5 year survival is 53% and the relapse rate 29%, with a medium follow-up for surviving patients of 1552 days (range 365-4094 days). In univariate analysis the following variables were found to be associated with an increased risk of failure: high-dose cyclosporin (CsA), M4-M6 FAB subtype and a long interval (> or = 180 days) between diagnosis and BMT. Other disease-related variables at presentation were not significant, including WBC count > 50 x 10(9)/l, marrow blasts < 70%, time to enter remission > 40 days and > 2 courses to enter remission. Survival was 58% vs 43% for M1-M3 vs M4-M6 FAB subtypes (p = 0.03) and 71% vs 42% for low-dose vs high-dose CsA (p = 0.01). A multivariate analysis was then run separately on survival, relapse and transplant related mortality (TRM). Survival was negatively influenced by M4-M6 FAB subtypes (p = 0.009), high-dose CsA (p = 0.03) and a long interval between diagnosis and BMT (p = 0.04). Leukemia relapse was higher in patients receiving high-dose CsA (p = 0.003) and in females (p = 0.04). Transplant-related mortality was higher in FAB M4-M6 patients (p = 0.01) and patients grafted late after diagnosis (p = 0.03).(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/8199567/Allogeneic_bone_marrow_transplantation_for_acute_myeloid_leukemia_in_first_complete_remission:_the_effect_of_FAB_classification_and_GVHD_prophylaxis_ L2 - http://www.diseaseinfosearch.org/result/4195 DB - PRIME DP - Unbound Medicine ER -